menu
    • menu
    [{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Undisclosed","graph3":"Vizient","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vizient \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Vizient \/ Pfizer Inc"},{"orgOrder":0,"company":"Vizient","sponsor":"Elutia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Agreement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Vizient","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vizient \/ Vizient","highestDevelopmentStatusID":"15","companyTruncated":"Vizient \/ Vizient"},{"orgOrder":0,"company":"Vizient","sponsor":"Baudax Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Vizient","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vizient \/ Vizient","highestDevelopmentStatusID":"15","companyTruncated":"Vizient \/ Vizient"},{"orgOrder":0,"company":"Vizient","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Vizient","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vizient \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Vizient \/ Pfizer Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Vizient

    Menu

    Vizient

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vizient

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Vizient

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Elutia

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners

                            Details : The agreement aims to provide access to Elutia’s innovative EluPro Antibiotic Eluting BioEnvelope, embedded with rifampin and minocycline, to S3P’s extensive network of 993 acute care facilities.

                            Product Name : EluPro

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            January 06, 2025

                            Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Elutia

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vizient

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Vizient

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Vizient Announces Novaplus Enhanced Supply Agreement with Pfizer for 7 Additional Essential Medications

                            Details : The medications under the agreement are Methotrexate Injection; Phytonadione Injectable Emulsion; Ceftriaxone for Injection; Labetalol Hydrochloride Injection; Midazolam Injection; Milrinone Lactate Injection; and Vancomycin Hydrochloride for Injection.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            December 03, 2020

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vizient

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Vizient

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meloxicam

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Baudax Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO®

                            Details : Baudax Bio has entered into a Pharmacy Supplier Agreement with Vizient, Inc. effective as of July 1, 2020, to offer ANJESO (meloxicam) injection, a non-opioid option for managing moderate to severe pain.

                            Product Name : Anjeso

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 20, 2020

                            Lead Product(s) : Meloxicam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Baudax Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vizient

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Vizient

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Vizient Announces Novaplus Enhanced Supply Agreement with Pfizer for Six Essential Medications

                            Details : Vizient has signed an agreement with Pfizer to add six drugs identified as “essential medications” to its Novaplus® Enhanced Supply Program, part of Vizient’s private label pharmacy solution.

                            Product Name : Precedex

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 22, 2020

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth